Chronic Hepatitis Articles & Analysis
15 news found
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
Preclinical data on ALVR107, an investigational VST to cure chronic hepatitis B, will be presented at the International Liver Congress in June. ...
ByKalaris
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
We’ve seen how our viral vector has transformed the world’s approach to sars-cov2 and has shown promising early results in chronic hepatitis B virus infection. We see this partnership as another important validation of our prime boost platform’s utility in oncology as well as infectious ...
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) ...
Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the group receiving low-dose nivolumab with the heterologous boost (VTP-300). ...
We also anticipate that initial clinical data on two of our chronic infectious disease therapeutic programs will be presented at scientific conferences next week,” commented Bill Enright, Vaccitech’s CEO. ...
” This workforce reduction follows Finch’s recent announcement that it has paused its chronic hepatitis B program and the announcement of a clinical hold by the FDA on its investigational new drug application for CP101 and associated delays to Finch’s recurrent CDI and ASD programs. ...
The programs include: A Phase 1/2 clinical trial of VTP-300 in patients with chronic hepatitis B virus (HBV) infection. The first patient in the trial was dosed in February 2021. ...
World Hepatitis Day takes place every year on July 28. Its purpose is to raise awareness of the disease worldwide and to provide information about the risks and the options for protection and treatment for hepatitis infections. The theme for this year’s World Hepatitis Day is “Find the Missing Millions.” Approximately 300 ...
Jena, Germany, July 28, 2018 — World Hepatitis Day takes place every year on July 28. Its purpose is to raise awareness of the disease worldwide and to provide information about the risks and the options for protection and treatment for hepatitis infections. The theme for this year’s World Hepatitis Day is “Find the Missing ...